Obstetrics & Gynecology:
Prevention of Preterm Birth in Triplets Using 17 Alpha-Hydroxyprogesterone Caproate: A Randomized Controlled Trial
Caritis, Steve N. MD1; Rouse, Dwight J. MD2; Peaceman, Alan M. MD3; Sciscione, Anthony MD4; Momirova, Valerija MS5; Spong, Catherine Y. MD6; Iams, Jay D. MD7; Wapner, Ronald J. MD8; Varner, Michael MD9; Carpenter, Marshall MD10; Lo, Julie MD11; Thorp, John MD12; Mercer, Brian M. MD13; Sorokin, Yoram MD14; Harper, Margaret MD15; Ramin, Susan MD16; Anderson, Garland MD17; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal–Fetal Medicine Units Network (MFMU)
From the Departments of Obstetrics and Gynecology, 1University of Pittsburgh, Pittsburgh, Pennsylvania; the 2Center for Women’s Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama; 3Northwestern University, Chicago, Illinois; 4Drexel University, Philadelphia, Pennsylvania; the 5George Washington University Biostatistics Center, Washington, DC; 6Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; 7Ohio State University, Columbus, Ohio; 8Columbia University, New York, New York; 9University of Utah, Salt Lake City, Utah; 10Brown University, Providence, Rhode Island; 11University of Texas Southwestern Medical Center, Dallas, Texas; 12University of North Carolina, Chapel Hill, North Carolina; 13Case Western University, Cleveland, Ohio; 14Wayne State University, Detroit, Michigan; 15Wake Forest University, Winston-Salem, North Carolina; 16University of Texas at Houston, Houston, Texas; and 17University of Texas Medical Branch, Galveston, Texas.
*For the other members of the NICHD MFMU who participated in this study, see the Appendix online at http://links.lww.com/A643.
Supported by grants from the 6Eunice Kennedy Shriver National Institute of Child Health and Human Development, (HD21410; HD27869; HD40512; HD27915; HD40485; HD34208; HD40500; HD34116; HD40560; HD40544; HD27917; HD27860; HD40545; HD53097; HD36801; HD34136).
The authors thank subcommittee members Elizabeth Thom, PhD, for protocol/data management and statistical analysis and Allison Northen, RN, and Margaret Cotroneo, RN, for protocol development and coordination between clinical research centers. The authors also thank Joyce A. Martin, MPH, National Center for Health Statistics, who supplied U.S. natality and infant mortality data.
Corresponding author: Steve N. Caritis, 300 Halket Street, Room 2229, Pittsburgh, PA 15213; e-mail: firstname.lastname@example.org.
Financial Disclosure The authors did not report any potential conflicts of interest.
OBJECTIVE: To assess whether 17 alpha-hydroxyprogesterone caproate reduces the rate of preterm birth in women carrying triplets.
METHODS: We performed this randomized, double-blinded, placebo-controlled trial in 14 centers. Healthy women with triplets were randomly assigned to weekly intramuscular injections of either 250 mg of 17 alpha-hydroxyprogesterone caproate or matching placebo, starting at 16–20 weeks and ending at delivery or 35 weeks of gestation. The primary study outcome was delivery or fetal loss before 35 weeks.
RESULTS: One hundred thirty-four women were assigned, 71 to 17 alpha-hydroxyprogesterone caproate and 63 to placebo; none were lost to follow-up. Baseline demographic data were similar in the two groups. The proportion of women experiencing the primary outcome (a composite of delivery or fetal loss before 35 0/7 weeks) was similar in the two treatment groups: 83% of pregnancies in the 17 alpha-hydroxyprogesterone caproate group and 84% in the placebo group, relative risk 1.0, 95% confidence interval 0.9–1.1. The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a gestational age cutoff for delivery was set at 32 or 28 weeks.
CONCLUSION: Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00099164
LEVEL OF EVIDENCE: I
Infants delivered before term account for the vast majority of perinatal mortality and morbidity. Among triplets, 45% deliver before 32 weeks of gestation, and perinatal mortality is 59 in 1,000 compared with 4 in 1,000 live births among singleton gestations delivered at term.1,2 Thus, the societal burden of prematurity and its attendant complications are high among fetuses from multifetal gestation. This high-risk group is one where interventions to reduce the rate of prematurity have met with little success. Treatment with 17 alpha-hydroxyprogesterone caproate (17-OHPC) reduced the risk of recurrent preterm birth in singleton gestations by one third.3 This treatment, however, proved ineffective in women with twin gestation.4 The current trial assesses the value of this therapy in a group of women at extremely high risk of preterm birth, those with triplet gestations.
MATERIALS AND METHODS
This placebo-controlled, double-blinded, randomized clinical trial was undertaken at 14 sites and targeted women with triplet gestations. Recruitment began in April 2004 and was completed in September 2006. Pregnant women with triplets were eligible if their gestational age was at least 16 weeks and no more than 20 weeks. Exclusion criteria were serious fetal anomalies, two or more fetuses in one amniotic sac, suspected twin-to-twin transfusion syndrome, marked ultrasonographic growth discordance (at least 3 weeks estimated gestational age difference between any two fetuses), planned nonstudy progesterone therapy after 16 weeks, in-place or planned cerclage, major uterine anomaly (eg, bicornuate uterus), unfractionated heparin therapy greater than 10,000 units/d, low molecular weight heparin therapy at any dose, and major chronic medical diseases (eg, insulin-requiring diabetes mellitus or pharmacologically treated hypertension). Triplet gestations that were the result of intentional fetal reduction from a quadruplet pregnancy were not excluded, but reductions from a higher order gestation were excluded.
An ultrasonographic examination between 12 weeks and 20 weeks 6 days of gestation was performed to screen for major fetal anomalies and to establish gestational age. For spontaneous conceptions, the duration of gestation at the time of randomization was determined according to a previously described algorithm on the basis of the last menstrual period and the results of ultrasonographic measurement of the largest fetus at the earliest ultrasound.5 For conceptions after assisted reproductive technologies, the duration of gestation was calculated based on the date of embryo transfer and the age of the embryos when transferred. The study was approved by the institutional review boards of each clinical site and of the data coordinating center. Consent was given by all participants before enrollment into the study. The trial is registered at ClincialTrials.gov (NCT00099164).
Eligible, consenting women were given a trial intramuscular injection of the placebo and returned for a randomization visit not later than 20 weeks 6 days of gestation. At that visit, women who remained eligible were assigned to receive identically appearing active (250 mg 17-OHPC in 1 mL castor oil) or placebo (1 mL castor oil) injections prepared by a research pharmacy. The simple urn method of randomization,6 with stratification according to clinical center, was used to create a randomization sequence for each center, and the boxes of 17-OHPC and placebo were packaged for each center according to the randomization sequences. The participating women, their caregivers, and the research personnel were not aware of the study group assignment. After entering the study, women returned for weekly injections through the end of the 34th week of gestation or until delivery, whichever occurred first. At each visit, they underwent systematic assessment for adverse effects. The usual clinical care provided to women in the study was not otherwise perturbed.
After delivery, study personnel reviewed delivery, newborn, and postpartum records and documented the date of delivery, birth weight of the infant, and neonatal course, as well as the occurrence of complications of pregnancy and obstetric interventions. Infants were followed until discharge from the hospital of birth, or if transferred, from the transfer hospital.
The primary study outcome was a composite of delivery or fetal loss before 35 completed weeks of gestation (245 days). Fetal loss included miscarriage, termination, or stillbirth occurring anytime after randomization. Secondary outcomes included selected individual maternal and neonatal outcomes and a composite of serious adverse neonatal outcomes. The composite of serious adverse neonatal outcomes included neonatal death, respiratory distress syndrome, culture-proven sepsis, necrotizing enterocolitis stage II or III, bronchopulmonary dysplasia, intraventricular hemorrhage grade III or IV, or periventricular leukomalacia or severe retinopathy of prematurity stage III or higher.
Statistical analysis was performed according to the intention-to-treat principle. For the primary outcome, the unit of analysis was the pregnancy, thus if any of the three fetuses died or was born before 35 weeks, the pregnancy was considered to have met the outcome. The proportions of women in each study group remaining pregnant with three live fetuses were compared using survival analysis adjusted for gestational age at entry.7 For baseline data, maternal outcomes and for the primary outcome where the pregnancy was the unit of analysis, continuous variables were compared using the Wilcoxon rank sum test, and categorical variables were compared with the χ2 or Fisher exact test as appropriate.
For neonatal binary outcomes, the unit of analysis was the neonate, with robust variance estimation used to account for the clustering of neonates within pregnancies. Log binomial regression was used to calculate relative risks. In cases with rare outcomes, the neonatal data were analyzed using the worst-per-pregnancy outcome. For birth weight, the Wei-Lachin generalization of the Wilcoxon test8 was used, again to account for correlation between the fetuses/neonates within a pregnancy. Where the baseline variables differed between the two groups, covariate adjustment was performed by stratified analysis.
On the basis of data from the U.S. Natality report for 2000 and data from one of the participating institutions, we estimated conservatively that in the placebo group, 80% of triplet gestations would deliver before 35 completed weeks gestation.8 Thus, a total sample size of 120 was deemed sufficient to detect a 33% reduction in the rate of delivery or loss before 35 weeks, under the assumptions of a type I error (two-tailed) of 5% and power of greater than 80%.
Before the study started, the group sequential method of Lan and Demets with the modified O’Brien-Fleming spending function was chosen for adjustment of the significance level in interim analyses.9 Three interim analyses were performed and in the final analysis of the primary outcome, two-tailed P values of less than 0.03 would be considered significant; however, 95% confidence intervals are reported. For all other outcomes, a nominal P value of P<.05 was considered significant, and no adjustments were made for multiple comparisons. An independent Data and Safety Monitoring Committee monitored the trial and reviewed the interim results.
We identified 241 eligible women, of whom 149 gave consent, and 134 (55.6% of those eligible) were randomly assigned—71 to the 17-OHPC group and 63 to the placebo group (Fig. 1). Outcome data were available for 100% of the assigned women, and for all of the 402 fetuses (Fig. 1). The baseline characteristics of the two study groups were similar (Table 1). There were no significant differences in any of the variables listed except race (P=.03).
Compliance with the intervention was defined as the ratio of the number of injections received to the number expected per protocol (number of whole weeks from randomization to delivery, or to 34 weeks 6 days gestation, whichever was first). Compliance was 95.6% in the 17-OHPC group and 97.0% in the placebo group (P=.08).
The rate of the primary outcome (delivery or fetal death before 35 weeks) did not differ between groups occurring in 83% (59 of 71) of pregnancies in the 17-OHPC group, and in 84% (53 of 63) in the placebo group, relative risk (RR) 1.0, 95% confidence interval (CI) 0.9–1.1 (Table 2). Results were similar when adjusted by race. Mean gestational age at delivery did not differ between groups, nor did the proportion of deliveries occurring before 32 or 28 weeks. Table 2 also compares each of the components of the primary outcome in the two treatment groups. The rates of spontaneous (48% and 43%) and indicated (35% and 41%) preterm births were similar in the 17-OHPC and in the placebo groups, respectively. There were seven fetal losses from the time of randomization to 34 6/7 weeks, one in the 17-OHPC group and six in the placebo group. There were no fetal losses after 35 weeks. The fetal death in the 17-OHPC group was associated with multiple malformations. The six fetal losses in the placebo group occurred in three pregnancies; in one, delivery occurred at 23 weeks secondary to preeclampsia and preterm labor and all three fetuses died during labor. In the other two pregnancies, the deaths were unexplained and the remaining fetuses survived. Figure 2 depicts the proportion of randomly assigned participants who remained undelivered and with three living fetuses according to the gestational age and treatment group. The two groups were similar (P=.743). Table 3 summarizes selected maternal outcomes and interventions; there were no significant differences between the two groups.
The rate of the serious adverse composite neonatal outcome (neonatal death, severe retinopathy of prematurity, respiratory distress syndrome, early onset neonatal culture-proven sepsis, necrotizing enterocolitis stage II or III, bronchopulmonary dysplasia, intraventricular hemorrhage grade III or IV, or periventricular leukomalacia) was 37% in the 17-OHPC group compared with 34% in the placebo group, RR 1.1, 95% CI 0.7–1.7 (Table 4). Table 4 also summarizes selected neonatal outcomes according to treatment group. There were five neonatal deaths among four of the pregnancies treated with 17-OHPC. These newborns were delivered at 24 (two neonates), 25, 30, and 32 weeks. All died due to complications of prematurity. The pregnancy delivered at 24 weeks was the same pregnancy with the fetal demise associated with multiple anomalies. There were two neonatal deaths in the placebo group in two separate pregnancies. Both infants were delivered at 25 weeks and died of complications of prematurity. Likewise, the rates of individual outcomes were similar in the two treatment groups (Table 4). There was a greater proportion of infants in the 17-OHPC group with a birth weight less than 1,500 g; the difference was statistically significant (43% compared with 25%, RR 1.7, 95% CI 1.1–2.7). However, there was no overall difference in birth weight (as a continuous variable, P=.142) or in the proportion of neonates with a birth weight of less than 2,500 g (RR 0.9, 95% CI 0.9–1.0).
Adverse effects were common in both groups (69% and 65% in the 17-OHPC and placebo group, respectively, RR 1.1, 95% CI 0.8–1.3), but were generally mild and, in the majority (64%) of women who experienced them were limited to pain, swelling, bruising, itching, or redness at the injection site. Three women (two in the 17-OHPC group and one in the placebo, P=.55) experienced adverse effects so severe that the injections were not continued. These adverse effects included constitutional symptoms and elevated liver enzymes (placebo participant) and intense injection site reactions (two 17-OHPC participants).
This randomized, placebo-controlled trial has demonstrated that 17-OHPC does not reduce the rate of preterm birth in women with triplet gestation. This lack of benefit occurred regardless of conception method. Combined with our companion study with twins,4 the findings of this study help to clarify further those conditions where 17-OHPC should be considered. Although, 17-OHPC reduces the rate of preterm birth in women with a singleton gestation who had a prior preterm birth, this treatment is ineffective in reducing the rate of prematurity in multifetal gestation. The mechanism of action of 17-OHPC in reducing preterm birth rates in singleton gestation is unclear. Consequently, explanations for why this therapy proved ineffective in multifetal gestations must remain speculative. We undertook this study because we hypothesized that 17-OHPC might affect a proposed mechanism for preterm parturition in multiples, that of uterine stretch. The degree of uterine stretch is greater in multiple than in singleton gestation, and it is well-documented that uterine stretch induces transcription of several contraction-associated proteins.10 These proteins, including oxytocin receptors, gap junctions (connexin 43), and cyclooxygenase (COX), characterize an activated myometrium. Progesterone inhibits formation of these contraction-associated proteins.11 Older studies in humans and animals suggest that 17-OHPC is more potent and has a longer lasting progestational effect than progesterone.12,13 This led us to postulate that 17-OHPC might suppress expression of those contraction-associated proteins better than endogenous progesterone and therefore might reduce the rate of preterm delivery among women with multifetal gestation.
The lack of benefit in multifetal gestation may be due to an inadequate dose of 17-OHPC. For this study and our study in twins, we administered 250 mg intramuscularly weekly, a dose identical to that used in our study of singletons.3 We chose to use this dose because the therapeutic concentration of 17-OHPC was and is still not known. The dose selected for the study of Meis et al3 in singletons was based on prior studies14 and a meta-analysis that suggested that 250 mg 17-OHPC might be effective in reducing preterm birth rates in high-risk women.15 If the 250 mg weekly dose achieves “therapeutic” levels in only a portion of women with singleton gestation, that might explain why the success rate in a study of Meis et al3 was only 33%. In the same vein, if the dose of 250 mg 17-OHPC weekly does not achieve therapeutic levels in a substantial percentage of women with singletons, it is conceivable that concentrations in women with multifetal gestation are even lower given the physiologic changes that occur in pregnancy, which generally enhance drug metabolism or elimination. Analysis of the relationship of 17-OHPC concentration and preterm birth rates is currently under investigation in both the women with triplet or twin gestation. This exploration should address those issues related to 17-OHPC dosing and success.
Another plausible explanation for the failure of 17-OHPC to reduce the rates of preterm birth in multifetal gestation may be that myometrial stretch, the proposed mechanism of preterm birth in multiples, is not altered by 17-OHPC. To our knowledge the effect of 17-OHPC on stretch regulated contraction-associated proteins has not been evaluated.
Clearly, any attempt to define the basis of failure of 17-OHPC in reducing preterm birth rates in multiples or in any other group of patients at increased risk of preterm birth is severely constrained by our lack of understanding of how this treatment works. We have defined the pharmacokinetics of 17-OHPC in multifetal gestation and have shown that the drug has a half-life of nearly 9 days (Caritis S, Venkataramanan R. Pharmacokinetics of 17-alpha hydroxyprogesterone caproate (17-OHPC) in women with twin gestation [meeting abstract]. Annual Meeting of the Society for Gynecologic Investigation. Reno, Nevada, 2007.). The long half-life likely represents slow release from the depot injection site. The mechanism of action of 17-OHPC, however, has remained elusive. The drug is no better than progesterone in activating progesterone-responsive genes through the classic hormone–hormone receptor pathway.16 Injection of 17-OHPC does not seem to significantly alter plasma progesterone or 17-hydroxyprogesterone concentrations.17 Thus, the beneficial effect of 17-OHPC is not likely mediated by an effect on any of these hormones. Clearly, more research is required to define the mechanism of action of this drug.
The results of our study and our companion study in twins provide information on fetal safety of 17-OHPC in pregnancy. In reviewing a recent New Drug Application for 17-OHPC, the U.S. Food and Drug Administration raised concern about fetal safety because in the study of Meis et al,3 a nonsignificant increase in fetal deaths (RR 1.5, 95% CI 0.3–7.3) was seen in the 17-OHPC group.18 In our study of twins, fetal deaths were more common in the 17-OHPC group but those differences were not statistically significantly different from the placebo-treated group (RR 1.4, 95% CI 0.6–3.2). In our triplet study, only one fetal death was seen in the 17-OHPC group from the time of enrollment to the study endpoint of 35 weeks, and the fetus had multiple malformations. Six fetal deaths were seen in the placebo group. Our studies in twins and triplets collectively, therefore, provide a measure of reassurance that 17-OHPC therapy does not increase the risk of fetal demise. Furthermore, we found similar rates of small for gestational age infants in our current study among the two treatment groups.
Another issue about 17-OHPC treatment raised by the study of Meis et al3 is addressed with the current study and our companion study in twins, the effect of castor oil on preterm birth rates.4 It has been suggested that the use of castor oil in the placebo group and as a diluent for 17-OHPC might confound findings of 17-OHPC trials by actually increasing uterine contractility through the smooth muscle effects of castor oil.19 Castor oil is a gastrointestinal stimulant only when taken orally and not likely to have any effect on smooth muscle when given intramuscularly, since ricinoleic acid, the active ingredient, is formed by hydrolysis in the gut.20 Furthermore, the mean gestational ages at delivery in the 17-OHPC and placebo groups were consistent with the gestational age at delivery of triplets reported in the U.S. Natality report of 2005.21 Similar findings were seen in our study with twins.
Adverse effects were common in this study and overwhelmingly associated with injection site symptoms, such as pain, itching, and bruising. These findings were similar to those we reported in our study of twins and singletons.3,4 We also tracked serious adverse effects, including outcomes such as maternal death, unplanned hospitalization, and neonatal deaths. There were no maternal deaths reported among our study of triplets or twins. Likewise, the rates of other serious adverse outcomes in these studies were similar in the 17-OHPC and placebo groups.
The application of 17-OHPC therapy to women at risk of preterm birth is supported by our trial in singletons3 and the meta-analysis of Keirse,15 which summarized the literature on the use of 17-OHPC to prevent preterm birth in earlier studies. This treatment unfortunately has been expanded to other groups of women deemed to be at high risk for preterm birth with the expectation that the treatment will work in all high-risk groups.22 The present study and our companion study in twins clearly point out that such expectations are unfounded and that prospective randomized trials are needed before expanding use of 17-OHPC to other at-risk groups.
In summary, we have shown that 17-OHPC, as prescribed in this trial, does not reduce the rate of preterm birth in triplets, and our companion study demonstrated a lack of benefit in twins. Women with multifetal gestation should therefore not be treated with 17-OHPC as a preventive for preterm birth unless new information emerges to alter that recommendation. Treatment with 17-OHPC seems to be safe for the mother and her fetus.
1. Alexander GR, Salihu HM. Perinatal outcomes of singleton and multiple births in the United States, 1995–98. In: Blickstein I, Keith G, editors. Multiple pregnancy. London (UK): Taylor and Francis; 2005. p. 3–10.
2. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2003 period linked birth/infant death data set. Natl Vital Stat Rep 2006;54:1–29.
3. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379–85.
4. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–61.
5. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342:534–40.
6. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials [published erratum appears in Control Clin Trials 1989;10:126]. Control Clin Trials 1988;9:345–64.
7. Cnaan A, Ryan L. Survival analysis in natural history studies of disease. Stat Med 1989;8:1255–68.
8. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984;79:653–61.
9. Lan KK, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659–63.
10. Ou CW, Orsino A, Lye SJ. Expression of connexin-43 and connexin-26 in the rat myometrium during pregnancy and labor is differentially regulated by mechanical and hormonal signals. Endocrinology 1997;138:5398–407.
11. Shynlova O, Mitchell JA, Tsampalieros A, Langille BL, Lye SJ. Progesterone and gravidity differentially regulate expression of extracellular matrix components in the pregnant rat myometrium. Biol Reprod 2004;70:986–92.
12. Davis ME, Wied GL. 17-Alpha-hydroxyprogresterone-caproate: a new substance with prolonged progestational activity; a comparison with chemically pure progesterone. J Clin Endocrinol Metab 1955;15:923–30.
13. Reifenstein EC Jr. Introduction of marked as well as prolonged biologic activity by esterification; 17-alpha-hydroxyprogesterone caproate, a unique progestational compound. Fertil Steril 1957;8:50–79.
14. Johnson JW, Austin KL, Jones GS, Davis GH, Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675–80.
15. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149–54.
16. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, et al. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol 2007;197:599.e1–7.
17. Reijnders FJ, Thomas CM, Doesburg WH, Rolland R., Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br J Obstet Gynaecol 1998;95:462–8.
19. Brancazio LR, Murtha AP, Heine RP. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;349:1087–8.
20. Thiery M, Baines CJ, Kierse MJ, editors. The development of methods for inducing labour. In: Chalmers I, Enkin M, Kierse MJ, editors. Effective care in pregnancy and childbirth.
Oxford (UK): Oxford University Press; 1989. p. 969–80.
21. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2004. Natl Vital Stat Rep 2006; 55: 1–101.
22. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol 2007; 197: 252.e1–4.
Supplemental Digital Content
© 2009 by The American College of Obstetricians and Gynecologists.